Navigation Links
Occlutech Clarifies Statement Regarding Favourable Opinion Obtained From AIPPI With Regard to Patents Held by AGA Medical
Date:4/17/2008

JENA, Germany, April 17 /PRNewswire/ -- Occlutech GmbH, the leading European manufacturer of cardiac occlusion devices today announced a clarification of a recent news release.

In a news release dated February 8th, 2008, Occlutech stated that it received an opinion from AIPPI the European "Association for the Protection of Intellectual Property" with regard to non infringement by Occlutech of certain European IP held by AGA Medical.

AIPPI has requested a clarification of this statement:

1) The name European International Association for the Protection of Intellectual Property was not stated correctly. The correct name is the "International Association for the Protection of Intellectual Property".

2) The opinion received by Occlutech which states that Occlutech is not infringing EP 0808138B1 and its Italian part 019020BE/2006 held by AGA Medical Corp was commissioned through the Italian National Group of AIPPI but not issued by AIPPI International itself. The opinion was issued by and in the name of three independent experts nominated by the Italian Group of AIPPI. The opinion was issued by the experts nominated by the Italian Branch of AIPPI and not by, in the name of or on behalf of AIPPI International or the Italian National Group of AIPPI.

The opinion was given without influence of Occlutech GmbH and the impartiality of the experts has subsequently been confirmed by the Italian Branch of AIPPI.

3) Such an independent opinion commissioned through AIPPI is an instrument aiming at giving the requiring party a qualified and impartial opinion. It does not represent an official opinion by AIPPI since AIPPI does not get involved in intellectual property disputes between parties on behalf or in favour of one of the parties.

Occlutech GmbH regrets that its communication was not clear with regard to the role of AIPPI in commissioning and receiving the opinion.

Occlutech GmbH develops and manufactures a wide range of occluders that are sold under the Occlutech Figulla N brand in over 40 countries in European and international markets. Clinical programs leading to regulatory approval in the US and Japan are underway.

Contact:

Robert Moszner

e-mail: robert.moszner@occlutech.com

Phone: +49-3641-67-51-20

Susanne Goransson

e-mail: info@occlutech.info

Phone: +46-704336521


'/>"/>
SOURCE Occlutech GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
2. Phlo Clarifies That Pre-Reverse Split Certificates Are Negotiable in Market Transactions
3. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
4. Oncothyreon announces effectiveness of shelf registration statement
5. WuXi PharmaTech (Cayman) Inc. Announces Filing of Registration Statement For Follow-On and Secondary Offering
6. Evotecs Registration Statement in Connection With its Proposed Acquisition of Renovis Declared Effective
7. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
8. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
9. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
10. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
11. APIC Statement on Need for Increased Prevention Measures for Healthcare-Associated Infections (HAIs)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... BOSTON , Feb. 16, 2017 /PRNewswire/ ... for rare genetic deficiencies that result in ... of a $41 million mezzanine round of ... Ipsen, OrbiMed, MPM Capital, New Enterprise Associates, ... an undisclosed public healthcare investment fund. Rhythm ...
(Date:2/15/2017)... ... February 15, 2017 , ... ... and Chief Commercial Officer with GenePeeks. Matt is a veteran life sciences ... a computational genomics company focused on identifying inherited disease risk in future generations. ...
(Date:2/15/2017)... , Feb. 15, 2017  NASA provider SpaceX ... mission to the  International Space Station  no earlier than ... the launch will begin at 8:30 a.m. on NASA ... SpaceX Dragon spacecraft will lift off on the ... NASA,s Kennedy Space Center in ...
Breaking Biology Technology:
(Date:2/8/2017)... 2017 Report Highlights ... The global synthetic-biology market reached nearly ... 2021, growing at a compound annual growth rate (CAGR) of ... the global markets for synthetic biology. - Analyses of global ... projections of compound annual growth rates (CAGRs) through 2021. - ...
(Date:2/7/2017)... 2017   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the latest ... highly flexible and award winning eClinical solution, is now ... is a proven Software-as-a-Service (SaaS) clinical research technology ... but also delivers an entire suite of eClinical tools ...
(Date:2/6/2017)... 6, 2017 According to Acuity Market ... border authorities to continue to embrace biometric and ... 2143 Automated Border Control (ABC) eGates and 1436 ... more than 163 ports of entry across the ... achieving a combined CAGR of 37%. APC Kiosks ...
Breaking Biology News(10 mins):